Clinical Trials Logo

Prostatic Neoplasms clinical trials

View clinical trials related to Prostatic Neoplasms.

Filter by:

NCT ID: NCT02516709 Completed - Prostate Cancer Clinical Trials

Linear Source Registry for Prostate Cancer

CaRePC
Start date: June 2015
Phase:
Study type: Observational [Patient Registry]

Ongoing follow up for subjects implanted with the Linear Source String for prostate cancer.

NCT ID: NCT02514213 Completed - Prostate Cancer Clinical Trials

Trial to Evaluate Safety and Immunogenicity of INO-5150 Alone or With INO-9012 in Men With Prostate Cancer

Start date: July 2015
Phase: Phase 1
Study type: Interventional

This is a phase I, open-label trial to evaluate the safety and immunogenicity of INO 5150 alone or in combination with INO-9012 when delivered intramuscularly (IM) followed by electroporation (EP) in men with biochemically relapsed prostate cancer.

NCT ID: NCT02512458 Completed - Clinical trials for Bone Metastatic Prostate Cancer

Study of the Effect of Chemotherapy With Cabazitaxel on Prostate Cancer

CABA-BONE
Start date: October 29, 2015
Phase: Phase 2
Study type: Interventional

This is a prospective, open-label, single arm translational study of cabazitaxel in bone Castration Resistant metastatic Pancreatic Cancer (mCRPC) patients. Patient will be treated with intravenous (iv) cabazitaxel 25mg/m2 every (q) 21days per standard clinical practice for up to 10 cycles or until disease progression or unacceptable toxicity or physician's decision or patient's consent withdrawal (whichever occurs first).

NCT ID: NCT02512185 Completed - Prostate Cancer Clinical Trials

Towards Optimal Prescription of Chemotherapy in Prostate Cancer

TOPCOP
Start date: July 2015
Phase:
Study type: Observational

This study will examine the impact of modern treatments for metastatic Castrate Resistant Prostate Cancer (mCRPC) on several relevant 'geriatric' domains such as daily function, objective physical function, and falls. Additionally, the investigators study whether frailty is associated with worse outcomes, and whether it is possible to predict the risk of severe chemotherapy toxicity in older men.

NCT ID: NCT02507570 Completed - Clinical trials for Prostate Carcinoma Metastatic to the Bone

Open Label Phase Two Study of Enzalutamide With Concurrent Administration of Radium Ra 223 Dichloride in Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Symptomatic Bone Metastasis

Start date: September 23, 2015
Phase: Phase 2
Study type: Interventional

This is an open label study designed to examine the effects of Enzalutamide with concurrent administration of Radium Ra 223 dichloride in Castrate-Resistant (Hormone-Refractory) Prostate Cancer subjects with symptomatic bone metastases in both the pre- and post-chemotherapy setting.

NCT ID: NCT02507427 Completed - Prostate Cancer Clinical Trials

Monitoring and Mapping of Erectile Nerve During RALP (MMEN Study)

Start date: July 26, 2015
Phase: Phase 1/Phase 2
Study type: Interventional

To evaluate the safety and efficacy of pelvic autonomic nerve monitoring and mapping during robot assisted laparoscopic radical prostatectomy for preservation of erectile function.

NCT ID: NCT02503748 Completed - Prostate Cancer Clinical Trials

Prostate Cancer E-Health-Tutorial

PROCET
Start date: July 2015
Phase: N/A
Study type: Interventional

In a participatory process involving urologists and former patients, the project team has developed an online information system ("tutorial") for patients with localized prostate cancer. In this field test, relevant outcomes are measured and the tutorial will be tested for its clinical applicability.

NCT ID: NCT02499848 Completed - Prostate Cancer Clinical Trials

Evaluate, Safety and Tolerability of Intraprostatic PRX302 Administration, Low to Intermediate Risk Prostate Cancer

Start date: July 2015
Phase: Phase 2
Study type: Interventional

To Evaluate Safety, Tolerability and Potential Efficacy of PRX302 effect on clinically significant localised low to intermediate prostate cancer.

NCT ID: NCT02499835 Completed - Clinical trials for Prostate Adenocarcinoma

Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer

Start date: July 1, 2015
Phase: Phase 1/Phase 2
Study type: Interventional

This randomized pilot trial studies vaccine therapy and pembrolizumab in treating patients with prostate cancer that does not respond to treatment with hormones (hormone-resistant) and has spread to other places in the body (metastatic). Vaccines made from deoxyribonucleic acid (DNA), such as pTVG-HP plasmid DNA vaccine, may help the body build an effective immune response to kill tumor cells. Monoclonal antibodies, such as pembrolizumab, may find tumor cells and help kill them. Giving pTVG-HP plasmid DNA vaccine and pembrolizumab may kill more tumor cells.

NCT ID: NCT02499497 Completed - Prostate Cancer Clinical Trials

A Selective Androgen Receptor Modulator for Symptom Management in Prostate Cancer

Start date: February 29, 2016
Phase: Phase 2
Study type: Interventional

This research study is studying the use of a targeted therapy called LY SARM, which is an investigational drug from a new class of molecules called Selective Androgen Receptor Modulators (SARMs) as a possible improvement in quality of life for participants who have undergone radical prostatectomy. Androgens are a group of hormones that play a role in male traits and reproductive activity. The names of the study interventions involved in this study are: - LY2452473